Abstract

Vitamin D 3 is metabolized into the hormonally active form, 1α,25-dihydroxyvitamin D 3 ( 1), via 25-hydroxyvitamin D 3 ( 2) which is the most abundant circulating metabolite. Introduction of the 1α-hydroxyl group into 25-hydroxyvitamin D 3 ( 2) to produce 1α,25-dihydroxyvitamin D 3 ( 1) increases the VDR binding affinity by approximately 1000-fold. The X-ray crystal structure of human VDR in complex with 1α,25-dihydroxyvitamin D 3 ( 1) shows that, together with Ser-237, the 1α-hydroxyl group of 1α,25-dihydroxyvitamin D 3 ( 1) makes hydrogen bonds with Arg-274, single mutation of which results in impaired ligand recognition. In 2002, lithocholic acid, which possesses a carboxyl group at position C24, was demonstrated to be a weak VDR ligand. We speculated that the carboxylic acid of lithocholic acid could be recognized by Arg-274 in the ligand-binding domain of VDR. In view of the significance of Arg-274 to direct the 1α-hydroxyl group, as well as the results with lithocholic acid and its derivatives, we designed the C2 modified analogues of 25-hydroxylvitamin D 3 ( 2) having a carboxyl group, instead of the 1-hydroxyl group, for better electrostatic interaction to the guanidinium side-chain of arginine.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.